Related Experiment Videos
[Octreotide therapy in multiple endocrine neoplasia type-1]
Zsuzsanna Valkusz1, László Gáspár, János Julesz
1Szegedi Tudományegyetem, Altalános Orvostudományi Kar, Endokrinológiai Onálló Osztály.
Orvosi Hetilap
|June 18, 2002
Summary
Octreotide therapy for multiple endocrine neoplasia type 1 (MEN1) effectively reduced gastrin levels in two patients. While parathormone levels decreased in one patient, they remained unchanged in the other, with no effect on prolactin or adrenal hormones.
Area of Science:
- Endocrinology
- Oncology
- Medical Therapy
Background:
- Multiple endocrine neoplasia type 1 (MEN1) is characterized by tumors in the parathyroid, pancreas, and pituitary glands.
- Patients often present with hyperparathyroidism, pancreatic tumors, and pituitary tumors, leading to hormone overproduction.
Observation:
- Two MEN1 patients with hyperparathyroidism and pancreatic tumors were treated with octreotide after failed surgical interventions.
- One patient received subcutaneous octreotide followed by long-acting octreotide (Sandostatin LAR), while the second received long-acting octreotide from the start.
- Associated conditions included hyperprolactinemia, prolactinoma, and nonfunctioning adrenal adenomas.
Findings:
- Octreotide treatment led to decreased serum gastrin in both patients.
- Serum parathormone levels decreased in the first patient but remained unchanged in the second.
- Prolactin and adrenocortical hormone levels were unaffected by octreotide therapy.
Implications:
- Octreotide demonstrates efficacy in managing hormonal imbalances in MEN1, particularly for gastrinomas.
- The variable effect on parathormone suggests a complex interplay of hormonal regulation in MEN1.
- Long-term octreotide therapy may offer a viable medical management option for MEN1 patients, improving symptom control.